Skip to main content

New medicines for tuberculosis

Objective

The explicit aim of the NM4TB project is to successfully develop new drugs for the treatment of tuberculosis (TB) with the following desired properties: * High potency to reduce treatment duration, * Activity against persistent bacilli, * Inhibition of ne w target classes, * Activity against multidrug resistant TB, * Specificity for Mycobacterium tuberculosis. This will be achieved through an integrated approach implemented by a team that combines some of Europe's leading academic TB researchers with a maj or pharmaceutical company and three SMEs with a strong commitment to discovering new anti-infective agents. Four interlinked, cutting-edge work packages (WP1) have been assembled: * WP1 provides all of the enabling technologies expected of a modern drug development programme, * WP2 is devoted to validation of an attractive range of targets, * WP3 generates three dimensional structures of targets with their inhibitors, * WP4 provides an exhaustive approach to screening and lead optimization culminating in candidate drugs. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas su ch as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two as-yet untouched areas of the physiology of M. tuberculosis signal transduction pathways and persistence.

Field of science

  • /medical and health sciences/clinical medicine/pneumology/tuberculosis
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance
  • /natural sciences/biological sciences/biochemistry/biomolecules/nucleic acid

Call for proposal

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
Address
Batiment Ce 3.316 Station 1
Lausanne
Switzerland

Participants (21)

UPPSALA UNIVERSITET
Sweden
Address
Sankt Olofsgatan 10 B
Uppsala
ASTRAZENECA
United Kingdom
Address
Mereside, Alderley Park
Macclesfield
QUEEN MARY & WESTFIELD COLLEGE
United Kingdom
Address
43 Rutland House, New Road
London
INSTITUT PASTEUR
France
Address
25-28 Rue Du Dr Roux
Paris
UNIVERSITÀ DEGLI STUDI DI PAVIA
Italy
Address
Strada Nuova, 65
Pavia
STATENS SERUM INSTITUT
Denmark
Address
Artillerivej 5
Copenhagen S
LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.HANS-KNÖLL-INSTITUT
Germany
Address
Beutenbergstrasse 11A
Jena
UNIVERSITY OF MANCHESTER
United Kingdom
Address
Oxford Road
Manchester
COMENIUS UNIVERSITY, FACULTY OF NATURAL SCIENCES
Slovakia
Address
Mlynska Dolina
Bratislava
UNIVERSITY OF ZURICH
Switzerland
Address
Raemistr. 71
Zurich
VICHEM CHEMIE RESEARCH LTD.
Hungary
Address
Herman Ottó U. 15
Budapest
ASTEX THERAPEUTICS LIMITED
United Kingdom
Address
436 Cambridge Science Park, Milton Road
Cambridge
NEED PHARMACEUTICALS
Italy
Address
Via Ariberto 17
Milano
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
United Kingdom
Address
Cranmer Terrace
London
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Rue Michel-ange, 3
Paris
A.N. BAKH INSTITUTE OF BIOCHEMISTRY OF THE RUSSIAN ACADEMY OF SCIENCES
Russia
Address
Leninsky Prospect, 33
COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH
South Africa
Address
Meiring Naudé Street
395
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
Trinity Lane, The Old Schools
Cambridge
ASTRA ZENECA INDIA PVT LTD
India
Address
'Avishkar',bellary Road,hebbal,
Bangalore
UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA
Spain
Address
Bª Sarriena S/n
Leioa
SCIPROM SARL
Switzerland
Address
Rue Du Centre 70
St-sulpice